Highlights of This Issue 2213

REVIEW

2215 New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects
Guadalupe Aparicio-Gallego, Moisés Blanco, Angélica Figueroa, Rosario García-Campelo, Manuel Valladares-Ayerbes, Enrique Grande-Pulido, and Luis Antón-Aparicio

THERAPEUTIC DISCOVERY

2224 Artesunate Induces Oxidative DNA Damage, Sustained DNA Double-Strand Breaks, and the ATM/ATR Damage Response in Cancer Cells
Nicole Berdelle, Teodora Nikolova, Steve Quiros, Thomas Efferth, and Bernd Kaina

2234 Direct Role of Adiponectin and Adiponectin Receptors in Endometrial Cancer: In Vitro and Ex Vivo Studies in Humans
Hyun-Seuk Moon, John P. Chamberland, Konstantinos Aronis, Sofia Tseleni-Balafouta, and Christos S. Mantzoros

2244 Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma
Cheri Cloninger, Andrew Bernath, Tariq Bashir, Brent Holmes, Nicholas Artinian, Teresa Ruegg, Lauren Anderson, Janine Masri, Alan Lichtenstein, and Joseph Gera

2257 Acquisition of Resistance toward HYD1 Correlates with a Reduction in Cleaved α4 Integrin Expression and a Compromised CAM-DR Phenotype
Michael F. Emmons, Anthony W. Gebhard, Rajesh R. Nair, Rachid Baz, Mark L. McLaughlin, Anne E. Cress, and Lori A. Hazlehurst

PRECLINICAL DEVELOPMENT

2266 Characterization of the Cellular and Antitumor Effects of MPI-0479605, a Small-Molecule Inhibitor of the Mitotic Kinase Msps1

2276 Integrin α6high Cell Population Functions as an Initiator in Tumorigenesis and Relapse of Human Liposarcoma
Lu Wang, Lingxian Wang, Yanhong Gu, Yongqian Shu, Yan Shen, and Qiang Xu

2287 Micelle-Encapsulated Thiotrepton as an Effective Nanomedicine for Inhibiting Tumor Growth and for Suppressing FOXM1 in Human Xenografts
Ming Wang and Andrei L. Gartel

2298 Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer

Yixian Zhang, Stephen Castaneda, Melissa Dumble, Maoliang Wang, Mary Mileski, Zhengxing Qu, Steven Kim, Victoria Shi, Patricia Kraft, Ying Gao, Jenny Pak, Puja Sapra, Raj Bandaru, Hong Zhao, Robert L. Vessella, Ivan D. Horak, and Lee M. Greenberger

The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice


Differential Expression of Uridine Phosphorylase in Tumors Contributes to an Improved Fluoropyrimidine Therapeutic Activity

Deliang Cao, Amy Ziemia, James McCabe, Ruilan Yan, Laxiang Wan, Bradford Kim, Michael Gach, Stuart Flynn, and Giuseppe Pizzorno

The Bcl-2/Bcl-X<sub>L</sub>/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo


Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models

Jae-Ho Cheong, Eun Sung Park, Jiyoung Liang, Jennifer B. Dennison, Dimitra Tsavachidou, Catherine Nguyen-Charles, Kwai Wa Cheng, Hassan Hall, Dong Zhang, Yiling Lu, Murali Ravoori, Vikas Kundra, Jaffer Ajani, Ju-Seog Lee, Wau Hin, and Gordon B. Mills

Vitamin E δ-Tocotrienol Augments the Antitumor Activity of Gemcitabine and Suppresses Constitutive NF-κB Activation in Pancreatic Cancer

Kazim Husain, Roni A. Francois, Teruo Yamauchi, Marta Perez, Said M. Sebti, and Mokenge P. Malafa

The Novel Bcl-2 Inhibitor ABT-737 Is More Effective in Hypoxia and Is Able to Reverse Hypoxia-Induced Drug Resistance in Neuroblastoma Cells

Tetyana Klymenko, Martin Brandenburg, Christopher Morrow, Caroline Dive, and Guy Makin

Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma

Brad C. McFarland, Jing-Yuan Ma, Catherine P. Langford, G. Yancey Gillespie, Hao Yu, Ying Zheng, Susan E. Noyzell, Dennis Huszar, and Etty N. Benveniste

Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008

Angela Nebbiosio, Raquel Pereira, Harshal Khanwalkar, Filomena Matarrese, José García-Rodríguez, Marco Miceli, Colin Logie, Valerie Kedinger, Felicetto Ferrara, Hendrik G. Stunnenberg, Angel R. de Lera, Hinrich Gröneweyer, and Lucia Altucci

Targeting Radiation-Induced G<sub>2</sub> Checkpoint Activation with the Wee-1 Inhibitor MK-1775 in Glioblastoma Cell Lines

Bhaswati Sarcar, Soumen Kahali, Antony H. Prabhu, Stuart D. Shumway, Yang Xu, Tim Demuth, and Prakash Chinnaiyan

The NEDD8-Activating Enzyme Inhibitor, MLN4924, Cooperates with TRAIL to Augment Apoptosis through Facilitating c-FLIP Degradation in Head and Neck Cancer Cells

Liqun Zhao, Ping Yue, Sagar Lonial, Fadlo R. Khuri, and Shi-Yong Sun

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway


MOLECULAR MEDICINE IN PRACTICE

MOLECULAR CANCER THERAPEUTICS
关于封面

人类肺微血管细胞与人类二倍体成纤维细胞共培养形成广泛的管网络，对VEGF的反应可以被免疫染色CD31，一种内皮细胞标记物。在cabozantinib（XL184）存在的情况下，一种小分子激酶抑制剂，对MET和VEGF受体2有强大的活动性，它被发现抑制了没有细胞毒性的情况下管形成。同样，cabozantinib抑制了正常细胞培养基中形成的管形成，这表明分泌的肿瘤细胞介导的血管生成生长因子不能绕过cabozantinib的抑制。详情，请参阅Yakes和同事在第2298页上的文章。